News
Post Doctoral Scientist post available at Boehringer - Research Beyond Borders working with the UK Cystic Fibrosis Gene Therapy Consortium
5 months ago The UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
5 months ago Flutterby Fundraisers to Sponsor Consortium Scientist
1 year ago New Publication - Gelinas et al 2017 - Media Supplements to Improve Lentiviral Vector Production Yields
1 year ago Gene Therapy Funding Update
1 year ago Consortium Student Live Facebook Interview from ASGCT
1 year ago
5 months ago The UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
5 months ago Flutterby Fundraisers to Sponsor Consortium Scientist
1 year ago New Publication - Gelinas et al 2017 - Media Supplements to Improve Lentiviral Vector Production Yields
1 year ago Gene Therapy Funding Update
1 year ago Consortium Student Live Facebook Interview from ASGCT
1 year ago
New Publication, Davies et al., 2014
Thursday, May 29th 2014
Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy, Davies et al., Hum Gene Therapy Clinical Development 25(2):97-107.
One of the crucial choices regarding the clinical delivery of our GL67/pGM169 formulation was the choice of nebuiliser.
Many different types of device are available and familiar to the CF community but only a few are useful for gene delivery. Lee Davies who led this work is an exceptional scientist and he designed these crucial studies to select the best avaiable nebuiliser for the trial.
View nebuliser image in new tab
Bacterial Lysate (2009): Neutralisation of a bacterial lysate. More...
